Fluoroquinolone Warnings
On July 26, 2016, the US Food and Drug Administration issued a recommendation to limit the use of fluoroquinolones, a group of powerful antibiotics. In the past three decades, FDA has approved levofloxacin (Levaquin), ciprofloxacin (Cipro), moxifloxacin (Avelox), norfloxacin (Noroxin), ofloxacin (Floxin), and gemifloxacin (Factive) to treat urinary tract infections (UTIs), acute bacterial sinusitis, and acute bacterial infection in people with COPD. In addition, these drugs have been used off-label to treat and prevent infections in cancer patients with low neutrophil counts, according to K. Kaur et al. The agency now says that the risk of serious, potentially permanent, adverse effects is greater than benefit for people with UTIs, sinusitis, and acute infections who have other treatment options. FDA recommends fluoroquinolone use only for serious infections such as anthrax, plague, and bacterial pneumonia.









0 Comments